Key clinical point: Neurofilament light, a blood biomarker of neurodegeneration, increased markedly in people destined to develop early-onset Alzheimer’s.
Major finding: Plasma NfL was higher in cognitively unimpaired mutation carriers than in noncarriers matched for age (18.08 pg/mL vs. 9.09 pg/mL, P less than .0001).
Study details: A cross-sectional cohort study of 2,144 mutation carriers and noncarriers, and longitudinal results from 504 carriers and noncarriers.
Disclosures: Several coauthors disclosed ongoing relationships with pharmaceutical manufacturers.
REPORTING FROM AAIC 2019